DCGI approved launch of Mylan Pharma Remdesivir in India at Rs.4,800 per 100 mg vial

Pharma major Mylan received approval for its Remdesivir from the Drug Controller General of India (DCGI). The company will launch a generic version of Gilead Sciences' COVID-19 anti-viral in the country at Rs.4,800 for 100 mg/vial.
The drug will be launched under the brand name Desrem in India and will be available to patients later this month at about 80% below the price tag for wealthy nations.
Mylan will manufacture remdesivir in India at its injectables facilities.
It has been inspected by the US Food and Drug Administration (FDA) for compliance with good manufacturing practices.
The efforts are aimed to accelerate access to critical medicine for patients with COVID-19 in India.